SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

JB Chemicals & Pharmaceuticals declines on reporting net loss of Rs 6.47 crore in Q3

12 Feb 2014 Evaluate

JB Chemicals & Pharmaceuticals is currently trading at Rs. 125.90, down by 4.05 points or 3.12% from its previous closing of Rs. 129.95 on the BSE.

The scrip opened at Rs. 126.20 and has touched a high and low of Rs. 129.50 and Rs. 119.15 respectively. So far 1,50,000 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 139.25 on 08-Jan-2014 and a 52 week low of Rs. 70.30 on 26-Mar-2013.

Last one week high and low of the scrip stood at Rs. 132.35 and Rs. 119.15 respectively. The current market cap of the company is Rs. 1,067.00 crore.

The promoters holding in the company stood at 55.87% while Institutions and Non-Institutions held 4.87% and 39.27% respectively.

The company has reported a net loss of Rs 6.47 crore for the third quarter ended December 31, 2013 as compared to net profit of Rs 21.87 crore for the same quarter in the previous year. However, total income of the company has increased by 17.24% at Rs 239.52 crore for quarter under review as compared to Rs 204.29 crore for the quarter ended December 31, 2012.

JB Chemicals & Pharmaceuticals is engaged in manufacturing of pharmaceutical specialties in various dosage forms, herbal remedies, diagnostics, generic drugs, active pharmaceutical ingredients (APIs).

JB Chem & Pharma Share Price

1997.35 22.65 (1.15%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×